Universität zu Köln

Howell, Jessica, Atkinson, Stephen R., Pinato, David J., Knapp, Susanne, Ward, Caroline, Minisini, Rosalba, Burlone, Michela E., Leutner, Monica, Pirisi, Mario, Buettner, Reinhard, Khan, Shahid A., Thursz, Mark ORCID: 0000-0002-8218-192X, Odenthal, Margarete and Sharma, Rohini (2019). Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma. Eur. J. Cancer, 116. S. 56 - 67. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852

Full text not available from this repository.

Abstract

Background: Hepatocellular carcinoma (HCC) is increasing globally. Prognostic biomarkers are urgently needed to guide treatment and reduce mortality. Tumour-derived circulating cell-free DNA (ctDNA) is a novel, minimally invasive means of determining genetic alterations in cancer. We evaluate the accuracy of ctDNA as a biomarker in HCC. Methods: Plasma cell-free DNA, matched germline DNA and HCC tissue DNA were isolated from patients with HCC (n = 51) and liver cirrhosis (n = 10). Targeted, multiplex polymerase chain reaction ultra-deep sequencing was performed using a liver cancer-specific primer panel for genes ARID1A, ARID2, AXIN1, ATM, CTNNB1, HNF1A and TP53. Concordance of mutations in plasma ctDNA and HCC tissue DNA was determined, and associations with clinical outcomes were analysed. Results: Plasma cell-free DNA was detected in all samples. Lower plasma cell-free DNA levels were seen in Barcelona Clinic Liver Cancer (BCLC A compared with BCLC stage B/C/D (median concentration 122.89 ng/mL versus 168.21 ng/mL, p = 0.041). 29 mutations in the eight genes (21 unique mutations) were detected in 18/51 patients (35%), median 1.5 mutations per patient (interquartile range 1-2). Mutations were most frequently detected in ARID1A (11.7%), followed by CTNNB1 (7.8%) and TP53 (7.8%). In patients with matched tissue DNA, all mutations detected in plasma ctDNA detected were confirmed in HCC DNA; however, 71% of patients had mutations identified in HCC tissue DNA that were not detected in matched ctDNA. Conclusion: ctDNA is quantifiable across all HCC stages and allows detection of mutations in key driver genes of hepatic carcinogenesis. This study demonstrates high specificity but low sensitivity of plasma ctDNA for detecting mutations in matched HCC tissue. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Howell, Jessica UNSPECIFIED UNSPECIFIED UNSPECIFIED Atkinson, Stephen R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pinato, David J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Knapp, Susanne UNSPECIFIED UNSPECIFIED UNSPECIFIED Ward, Caroline UNSPECIFIED UNSPECIFIED UNSPECIFIED Minisini, Rosalba UNSPECIFIED UNSPECIFIED UNSPECIFIED Burlone, Michela E. UNSPECIFIED UNSPECIFIED UNSPECIFIED Leutner, Monica UNSPECIFIED UNSPECIFIED UNSPECIFIED Pirisi, Mario UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Khan, Shahid A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Thursz, Mark UNSPECIFIED orcid.org/0000-0002-8218-192X UNSPECIFIED Odenthal, Margarete UNSPECIFIED UNSPECIFIED UNSPECIFIED Sharma, Rohini UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-136536
DOI:	10.1016/j.ejca.2019.04.014
Journal or Publication Title:	Eur. J. Cancer
Volume:	116
Page Range:	S. 56 - 67
Date:	2019
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	1879-0852
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language BETA-CATENIN; GENE-EXPRESSION; PLASMA DNA; AXIN1 Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/13653